SARS-CoV-2 mRNA Vaccine ARCT-021 clinical trials
Also written ARCT-021.
How each study uses SARS-CoV-2 mRNA Vaccine ARCT-021 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SARS-CoV-2 mRNA Vaccine ARCT-021 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Arcturus Therapeutics, Inc. (4) · Fred Hutchinson Cancer Center (1)
Often tested with
Tested in the same studies.
ARCT-165 (1) · Kostaive (1) · BNT162 Vaccine (1)
Studies
Open first, then newest update. How each study uses SARS-CoV-2 mRNA Vaccine ARCT-021 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant PatientsNot yet recruitingPhase 2Fred Hutchinson Cancer CenterNCT07390968Written as SARS-CoV-2 mRNA Vaccine ARCT-021
- A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy AdultsCompletedPhase 1/2Arcturus Therapeutics, Inc.NCT05037097Written as ARCT-021
- A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy AdultsTerminatedPhase 2Arcturus Therapeutics, Inc.NCT04668339Written as ARCT-021 single dose priming
- Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021TerminatedPhase 2Arcturus Therapeutics, Inc.NCT04728347Written as ARCT-021
- Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult SubjectsCompletedPhase 1/2Arcturus Therapeutics, Inc.NCT04480957Written as ARCT-021 Dose 1